Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC). However, aglycosylated Atezolizumab is unstable...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Maohua, Zhao, Rongqing, Chen, Jianxin, Tian, Wenzhi, Xia, Chenxi, Liu, Xudong, Li, Yingzi, Li, Song, Sun, Hunter, Shen, Tong, Ren, Wenlin, Sun, Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952408/
https://www.ncbi.nlm.nih.gov/pubmed/33707569
http://dx.doi.org/10.1038/s41598-021-85329-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952408/
https://www.ncbi.nlm.nih.gov/pubmed/33707569
http://dx.doi.org/10.1038/s41598-021-85329-9

Ejemplares similares